# A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

> **NCT01390441** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** MK-8808
- **BIOLOGICAL:** MabThera® (rituximab)
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Rituxan® (rituximab)
- **DRUG:** Methylprednisolone
- **DRUG:** Acetaminophen
- **DRUG:** Loratadine

## Key facts

- **NCT ID:** NCT01390441
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** The study was terminated early by the Sponsor for business reasons.
- **Last updated:** 2016-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01390441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01390441, "A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01390441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*